SVB Securities analyst David Risinger maintained a Buy rating on Halozyme (HALO - Research Report) on August 15 and set a price target of $52.00. The company's shares closed yesterday at $43.41.According to TipRanks, Risinger is a 2-star analyst with an average return of 2.5% and a 55.56% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Halozyme with a $54.60 average price target, representing a 25.78% upside.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-halozyme-halo?utm_source=advfn.com&utm_medium=referral
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Halozyme Therapeutics Charts.